Chemoprevention with special reference to inherited colorectal cancer.
Familial Adenomatous Polyposis (FAP) is a model for the adenoma-carcinoma sequence in several respects. One important area in which FAP serves as a model is chemoprevention. Early prevention trials mainly utilized micronutrients and were largely unsuccessful in preventing or causing regression of adenomas. A new era was ushered in by the recognition that antiarthritic doses of a nonsteroidal anti-inflammatory agent (NSAID), sulindac, could actually induce regression of colorectal adenomas in patients with FAP. Follow-up studies showed positive but variable long-term efficacy for colorectal adenomas, but sulindac appears to lack significant benefit in regressing duodenal adenomas or preventing initial occurrence of adenomas in APC mutation carriers. Due to the well-known side effects of traditional NSAIDs, selective COX-2 inhibitors have been studied rather extensively. Celecoxib has shown benefit in regressing colorectal adenomas and appears to have some duodenal activity as well. Rofecoxib, in smaller trials, showed efficacy as well. However, the entire field of NSAID research in chemoprevention is undergoing reexamination in light of recent demonstration of cardiovascular toxicity in nonfamilial or sporadic adenoma prevention trials. Whether NSAIDs will have a significant future in FAP chemoprevention will depend on a sober assessment of risks and benefits. These same issues will likely foster a more intensive search for new agents. FAP will undoubtedly continue to have a lead role in the testing of new agents, both in the interest of FAP management as such, and in anticipation of trials in nonfamilial adenomas, a problem with even greater societal impact. The historical development of chemoprevention in FAP will be presented, with an emphasis on issues of trial design.
Department of Gastrointestinal Medicine and Nutrition - 436, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-1402, USA. plynch@mdanderson.org
Patrick M
PM
Lynch
D011125:Adenomatous Polyposis Coli / Q000150:complications*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000970:Antineoplastic Agents; D001205:Ascorbic Acid / Q000627:therapeutic use; D000068579:Celecoxib; D018890:Chemoprevention / Q000379:methods*; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000178:diet therapy / Q000235:genetics* / Q000517:prevention & control*; D003474:Curcumin / Q000627:therapeutic use; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D000518:Eflornithine / Q000627:therapeutic use; D006801:Humans; D007783:Lactones / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D013450:Sulfones / Q000627:therapeutic use; D013467:Sulindac / Q000627:therapeutic use; D014815:Vitamins / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000970:Antineoplastic Agents; D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; D014815:Vitamins; C116926:rofecoxib; D013467:Sulindac; D003474:Curcumin; D000068579:Celecoxib; D001205:Ascorbic Acid; D000518:Eflornithine